This is what the package insert for Afrezza says:
“In clinical trials, two cases of lung cancer, one in controlled trials and one in uncontrolled trials (2 cases in 2,750 patient-years of exposure), were observed in participants exposed to AFREZZA while no cases of lung cancer were observed in comparators (0 cases in 2,169 patient-years of exposure). In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell) occurred in non-smokers exposed to AFREZZA and were reported by investigators after clinical trial completion. These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk for lung cancer, consider whether the benefits of AFREZZA use outweigh this potential risk.”
Afrezza was developed by a person with type 1 diabetes, Al Mannkind. Mannkind Corporation is not affiliated with all of the large other pharmaceutical companies, so when Afrezza came out, those companies did everything they could to suppress it. It is difficult to weed through the information online and that doctor’s provide to determine how safe Afrezza is because there were so many parties that wanted Afrezza to do poorly. In addition, there appear to be issues with people shorting the stocks- basically betting that they would do poorly, and then those people did everything they could to make that happen. This is what I’ve heard anyway, I didn’t learn of Afrezza until well after Afrezza was first released. Most doctor’s have no experience prescribing it, so they’re only repeating what they’ve been told by others.
I can’t say whether there are carcinogenic effects or not, but honestly, I’m more worried about the pollution in my home city impacting my lungs than Afrezza.
When I asked my doctor if I could try it, he said that they’re still learning about the effects of Afrezza. He was willing to prescribe it to me but wanted me to understand that there were some unknowns. He has two patients that use it, but both patients came to him first asking about it. I’ve been using it for about 2 years, and I seem to be doing fine. My follow-up spirometry test was in the same range as the one I did before I started using Afrezza. The clinical trials mentioned above were published in 2014, and performed even in the early 2000s. I haven’t seen any other reports of possible carcinogenic effects since.
I came across this paper recently which is quite dense and long, but it describes in-depth the 4 cancer cases on the Afrezza insert. It seems that many people in the trial were from other countries - eastern Europe specifically.
http://www.diabetesincontrol.com/wp-content/uploads/2014/04/www.fda.gov_downloads_AdvisoryCommittees_CommitteesMeetingMaterials_Drugs_EndocrinologicandMetabolicDrugsAdvisoryCommittee_UCM390864.pdf
Page 82 has the following text:
"Dr. Pai-Scherf stated “Lung cancer is the most common cancer in the world and the leading cause of cancer-related mortality. According to the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) statistics, the overall age-adjusted lung and bronchogenic cancer incidence rate during 2006-2010 was 61.4 per 100,000 men and women per year in United States. This rate corresponds to an annual incidence rate of 0.06%. The median age at diagnosis was 73 years. The incidence of lung and bronchus cancer increases rapidly after the age of 55 and is highest between the ages of 65-74. The Afrezza pooled safety population is based on trials conducted internationally. Based on World Health Organization (WHO), the age-standardized incidence rate of lung cancer is highest in Eastern Europe and Eastern Asia compared to North America.’
‘A close examination of the four cases of lung cancer reported in the Afrezza TI program indicates that demographics and the available characteristics are consistent with what would be expected in this population. However, the current available evidence does not allow a meaningful analysis regarding the risk of lung cancer in patients exposed to Afrezza TI because of small numbers and confounding factors.'"
This has actually not been a problem for me at all. The dosing is very different, but I personally wouldn’t use the term imprecise. I remember when I only used Humalog that when I was trending upwards fast, I had two choices: give a heavy dose of insulin now and then head off the low that happens a couple of hours later, or give the right dose and have to wait hours to get back in range.
Now I can get back in range quickly without the same worries about a low. Which means that my body is spending more time in a healthy range, reducing the probability of my developing complications long-term.
I could talk all day about why I love Afrezza, but it being needle-less would not be the focus of that discussion. I adjusted to giving myself shots when I was young. So the main benefit of it being needle-less is that I don’t have to do them in front of others when I’m out being social. That’s nice, but I can see why people might not think Afrezza is worth it if that is the only benefit they’re perceiving. Afrezza takes some getting used to, but the option to bring my blood glucose in range within an hour without having to worry about lows - it is really hard to describe to someone who hasn’t used it before.
Afrezza has made some aspects of diabetes a lot easier- primarily exercise. It’s out of my system within 1.5-2 hours, so I can go swimming or hiking without having insulin on board. I use Lantus 2x a day in the morning and evening, and that is less affected by exercise than Humalog or Novolog. So I don’t end up plummeting after a hard workout in the way I would if I had active fast-acting insulin on board.
Let me be clear though: I still use Humalog sometimes. Afrezza works best when my basal is strong. As a woman in my thirties, I have to adjust my basal throughout my monthly hormone cycle 20-25%. I am less sensitive to insulin right before my period, and more sensitive around a week afterward, but the patterns are not absolute. I tend to favor Humalog when I suspect my lantus dose is insufficient and should’ve been increased.
I also use Humalog when I’m about to have a meal that I think will take longer to digest. The benefit of having Afrezza on hand is that if I realize my dose was not enough, I can give a little Afrezza and see the effects within minutes.
Anyway, there’s a long answer to your short question 